| Top 50 Most Viewed Posts This Week |
|---|
|
Today This Week Last Week This Month Last Month
|
1. ohm20: OHM Thoughts??????????!!!!!! I have no idea what (2228)  (2) |
| 2. My69z: PD-L1 journey clarity.... Basket Study of (724) (3) |
| 3. skezan: I guess the FDA approval of lenacapavir explains (705) (15) |
| 4. Hanman: Because it will cost about $28K per year per (703) (4) |
| 5. My69z: This abstract answers alot: Doubling the mOS (685) (6) |
| 6. sunray3: And yet here the Gates foundation is endorsing (670) |
| 7. My69z: Hiv resevoir new grant: 6/1/25 *Thus, there is an (619) (6) |
| 8. Mr3Putt: Count me among the folks who were not aware of (605) (3) |
| 9. Carsmax177: IMO the PR from the company today about the first (601) (15) |
| 10. Figgs: I would like to know what's going on there. (596) (5) |
| 11. KenChowder: Note from Max Lataillade on LinkedIn in response (595) (39) |
| 12. biloxiblues: Summary of Leronlimab’s Path and Regulatory (590) (9) |
| 13. My69z: 3 yrs ago -- ICI Agreement with major institution (559) (8) |
| 14. Scuffler: In response to the conversation about PR- Been (533) (20) |
| 15. Evil Rabbit: You’re being way too kind. Thank you. We all (530) (12) |
| 16. Scuffler: Understood. But I think the lack of more (528) (8) |
| 17. ohm20: How about this because I can’t figure this one (510) (10) |
| 18. Mr3Putt: Abstract is up: 134eP - Observed survival (508) (11) |
| 19. skezan: "I would like to know what's going on there. " (506) (2) |
| 20. chazzledazzle: LATCH, PrEP might actually explain why we claim (503) (3) |
| 21. KenChowder: Abstract is released tomorrow at 6:05 Eastern (498) (8) |
| 22. HHIGambler: The Syneos partnership was announced almost a (495) (5) |
| 23. Riztheinvestor: https://investorshangout.com/images/MYImages/5457 (494) (6) |
| 24. My69z: Key FDA Oncology Initiatives: Project Optimus: (493) (8) |
| 25. misiu143: Few patients with TNBC used 700 mg , and of (491) (10) |
| 26. Riztheinvestor: I’m letting it rip today bad 100k or more maybe (491) (2) |
| 27. hoops: https://clinicaltrials.gov/study/NCT06699836?...y (488) (1) |
| 28. Mr3Putt: (488) (4) |
| 29. My69z: " The groups are discussing ordering vaccines (484) (1) |
| 30. MGK_2: I think you're referencing (483) (16) |
| 31. MGK_2: He mentions the potential for "yearly PrEP" on (481) (3) |
| 32. chazzledazzle: Like others, I was hoping for more (480) (6) |
| 33. MGK_2: I'll take you back to that original (480) (8) |
| 34. My69z: Slice n dice it: * "The study builds on the (479) (5) |
| 35. Katangolo: That just gave me PTSD. I had a professor who I (477) (8) |
| 36. Riztheinvestor: There he is. Nice! “In specific aim 1, we will (476) (5) |
| 37. Riztheinvestor: Big moment today…. Warner sorry Werner, pointed (474) (3) |
| 38. Ganesha: "Just one patient survived." Yes, but dosage was (471) (18) |
| 39. Vintool: Interesting little article. Lots of stuff in the (470) (3) |
| 40. Mr3Putt: They are doing a review early on and if the data (464) (13) |
| 41. Riztheinvestor: Agree. Idk how fast this timeline will be. Well (464) |
| 42. My69z: Thankful no ICI's were given. It would have gave (463) (5) |
| 43. ohm20: I still do not understand why we are dosing half (457) (17) |
| 44. brentie: Craig, (456) (3) |
| 45. sunray3: Just looked into it further, that would be Trevor (456) (1) |
| 46. brentie: Positives: First patient dosed in Phase II trial (455) (7) |
| 47. misiu143: Yes , doses were suboptimal , and at this time no (454) (19) |
| 48. MidnightRider: Feels like we've been in the desert 40 days....I (451) (8) |
| 49. Werner: Indeed...and what kind of a partner!! Syneos (451) |
| 50. Mr3Putt: They’d have to PR that kind of news w/in a few (450) |
